E-LIB Suche - Ergebnisse für: Gerson, James N.

1

Bendamustine as Lymphodepletion for Brexucabtagene Autoleuc..:

Chong, Elise A. ; Chong, Emeline R. ; Therwhanger, Dylan...
Transplantation and Cellular Therapy. 30 (2024) 7 - p. 726.e1-726.e8 , 2024

Link: https://doi.org/10.1016/..

2

T cell lymphoma and secondary primary malignancy risk after..:

Ghilardi, Guido ; Fraietta, Joseph A. ; Gerson, James N....
Nature Medicine. 30 (2024) 4 - p. 984-989 , 2024

Link: https://doi.org/10.1038/..

3

Bendamustine lymphodepletion before axicabtagene ciloleucel..:

Ghilardi, Guido ; Paruzzo, Luca ; Svoboda, Jakub...
Blood Advances. 8 (2024) 3 - p. 653-666 , 2024

Link: https://doi.org/10.1182/..

4

Immunologic Predictors of Vaccine Responsiveness in Patient..:

Chong, Elise A ; Kumashie, Kingsley Gideon ; Chong, Emeline R...
The Journal of Infectious Diseases. 230 (2024) 1 - p. 15-27 , 2024

Link: https://doi.org/10.1093/..

5

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-C..:

Scarfò, Lydia ; Patel, Manish R. ; Eyre, Toby A....
HemaSphere. 7 (2023) S3 - p. e852670f , 2023

Link: https://doi.org/10.1097/..

6

Impact of diagnosis to treatment interval in patients with ..:

Epperla, Narendranath ; Switchenko, Jeffrey ; Bachanova, Veronika...
Blood Advances. 7 (2023) 11 - p. 2287-2296 , 2023

Link: https://doi.org/10.1182/..

7

Salvage radiotherapy for relapsed/refractory non‐Hodgkin ly..:

Yegya-Raman, Nikhil ; Wright, Christopher M. ; LaRiviere, Michael J....
Clinical and Translational Radiation Oncology. 39 (2023) - p. 100587 , 2023

Link: https://doi.org/10.1016/..

8

Survival Outcomes for Patients with Relapsed/ Refractory Ag..:

Landsburg, Daniel J. ; Nasta, Sunita D. ; Svoboda, Jakub...
Transplantation and Cellular Therapy. 29 (2023) 8 - p. 495-503 , 2023

Link: https://doi.org/10.1016/..

9

Outcomes of patients with blastoid and pleomorphic variant ..:

Gerson, James N. ; Handorf, Elizabeth ; Villa, Diego...
Blood Advances. 7 (2023) 24 - p. 7393-7401 , 2023

Link: https://doi.org/10.1182/..

10

CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Re..:

Coombs, Catherine C. ; Pagel, John M. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S268-S269 , 2022

Link: https://doi.org/10.1016/..

11

Poster: CLL-120 Pirtobrutinib, A Highly Selective, Non-Cova..:

Coombs, Catherine C. ; Pagel, John M. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S140 , 2022

Link: https://doi.org/10.1016/..

12

Poster: MCL-133 Pirtobrutinib, a Highly Selective, Non-Cova..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S175 , 2022

Link: https://doi.org/10.1016/..

13

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Re..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S394-S395 , 2022

Link: https://doi.org/10.1016/..

14

Mutation analysis performed on tumor biopsies from patients..:

Landsburg, Daniel J. ; Morrissette, Jennifer J.D. ; Schuster, Stephen J....
Oncotarget. 13 (2022) 1 - p. 1237-1244 , 2022

Link: https://doi.org/10.18632..

15

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, N..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S118 , 2022

Link: https://doi.org/10.1016/..